Enforcement record

改善指導 disclosure naming バイエル薬品株式会社

バイエル薬品株式会社 (医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律)

This page records one action from a Japanese government disclosure, including the published name, governing law, authority, action details, and official source.

Ask about this record
医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律Ministry of Health, Labour and WelfareGovernment disclosure29 September 2017

Action type

改善指導

Law

医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律

Authority

Ministry of Health, Labour and Welfare

Action date

29 September 2017

Current page: Enforcement record

This screen focuses on one disclosed action: the published name, governing law, authority, facts, source status, and review evidence.

Source verification

Public-source and preservation status

Publishing authority
Ministry of Health, Labour and Welfare
Official source URL
Recorded by RegBase
Entity match
Not confirmed; shown under the published name
Kiroku preservation
Queued for preservation
Captured: Jul 12, 2026, 03:32 PM JST

“Confirmed” means that RegBase matched this record to the cited public disclosure or entity under the stated checks. It does not verify the truth of the disclosure or guarantee the entity’s current status, creditworthiness, or any legal conclusion.

Available sources and saved files are listed in the public documents section below.

Direct inquiry

Ask about this enforcement record

No account needed

Ask us to explain the record, verify the named legal entity, or scope a documented review.

Inquiry context: バイエル薬品株式会社

No phone number or account is required. We normally reply within two to three business days. Read our privacy policy.

English public-record screening

Need a documented check for バイエル薬品株式会社?

Get a structured English summary of the company identity and public records collected by RegBase, with source links, confirmation dates, and a clearly stated scope.

  • ✓ English and Japanese company identity
  • ✓ Enforcement and public-record summary
  • ✓ Official-source URLs and confirmation dates
  • ✓ PDF or CSV for an internal review file

This is not a credit report, safety guarantee, sanctions conclusion, legal opinion, or full due-diligence investigation.

No account required. The report opens immediately after Stripe confirms payment.

See sample screeningView pricingAsk a Japan-based researcher

Public documents and saved materials

View the original publications, see what was preserved, or download each file below.

Loading materials…

Need help interpreting these materials or confirming which legal entity they belong to? Ask RegBase about this company.

Action summary

Company
バイエル薬品株式会社Japanese only
Original: バイエル薬品株式会社
Governing law
医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律
医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律
Action type
改善指導
改善指導
Action date
29 September 2017
Issuing authority
Ministry of Health, Labour and Welfare
厚生労働省
Industry context
医薬品

Violation

Machine-translated summary — verify against original

Delayed adverse effect reporting occurred for the pharmaceuticals: Xarelto, Biaaspirin (anticoagulant), Stivarga, Nexavar (anticancer drugs)

Show original Japanese text

副作用報告の遅延が生じた医薬品：イグザレルト、バイアスピリン（抗血液凝固剤）、スチバーガ、ネクサバール（抗がん剤）

Compliance context

Context needed

This is a public Japanese regulatory disclosure. The exact legal effect depends on the cited source and regulator.

Japanese regulatory disclosure under 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律.

Review the original Japanese source and determine relevance to your counterparty-risk workflow.

This context is an operational aid for review workflows, not a credit opinion or legal conclusion.

Language

日本語版を見る (Japanese)

About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.